[American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer].
作者信息
Azzoli Christopher G, Baker Sherman, Temin Sarah, Pao William, Aliff Timothy, Brahmer Julie, Johnson David H, Laskin Janessa L, Masters Gregory, Milton Daniel, Nordquist Luke, Pfister David G, Piantadosi Steven, Schiller Joan H, Smith Reily, Smith Thomas J, Strawn John R, Trent David, Giaccone Giuseppe
机构信息
Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
出版信息
Zhongguo Fei Ai Za Zhi. 2010 Mar;13(3):171-89. doi: 10.3779/j.issn.1009-3419.2010.03.15.
Abstract
摘要
相似文献
1
[American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer].
Zhongguo Fei Ai Za Zhi. 2010 Mar;13(3):171-89. doi: 10.3779/j.issn.1009-3419.2010.03.15.
2
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.
J Oncol Pract. 2017 Dec;13(12):832-837. doi: 10.1200/JOP.2017.026716. Epub 2017 Aug 29.
3
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
J Clin Oncol. 2017 Oct 20;35(30):3484-3515. doi: 10.1200/JCO.2017.74.6065. Epub 2017 Aug 14.
4
American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.
J Clin Oncol. 2004 Jan 15;22(2):330-53. doi: 10.1200/JCO.2004.09.053. Epub 2003 Dec 22.
5
Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stages I to IIIA Resectable Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update Summary.
J Oncol Pract. 2017 Jul;13(7):449-451. doi: 10.1200/JOP.2017.022251. Epub 2017 Apr 25.
6
Maintenance chemotherapy in non-small cell lung cancer.
Ann Oncol. 2006 Mar;17 Suppl 2:ii67-70. doi: 10.1093/annonc/mdj928.
7
2015 American Society of Clinical Oncology annual meeting.
Lancet Respir Med. 2015 Jul;3(7):516-7. doi: 10.1016/S2213-2600(15)00244-1. Epub 2015 Jun 12.
8
Update: NCCN non-small cell lung cancer clinical practice guidelines.
J Natl Compr Canc Netw. 2004 Sep;2 Suppl 3:S-9-13.
9
Impact of the ASCO 2007 presentation of HOG Lun 01-24/USO-023 on the prescribing plans of American medical oncologists for patients with stage IIIB non-small cell lung cancer.
J Thorac Oncol. 2009 Aug;4(8):983-7. doi: 10.1097/JTO.0b013e3181adeefb.
10
[Management of nonresectable non-small cell lung cancer. Recommendations of the American Society of Clinical Oncology (ASCO)].
Bull Cancer. 1998 Feb;85(2):125-7.
引用本文的文献
1
Genomic Profiling of Driver Gene Mutations in Chinese Patients With Non-Small Cell Lung Cancer.
Front Genet. 2019 Oct 18;10:1008. doi: 10.3389/fgene.2019.01008. eCollection 2019.
2
MassARRAY, pyrosequencing, and PNA clamping for EGFR mutation detection in lung cancer tissue and cytological samples: a multicenter study.
J Cancer Res Clin Oncol. 2016 Oct;142(10):2209-16. doi: 10.1007/s00432-016-2211-7. Epub 2016 Aug 17.
3
A multicenter randomized controlled open-label trial to assess the efficacy of compound kushen injection in combination with single-agent chemotherapy in treatment of elderly patients with advanced non-small cell lung cancer: study protocol for a randomized controlled trial.
Trials. 2016 Mar 8;17(1):124. doi: 10.1186/s13063-016-1231-6.
4
Health Resource Utilization in Patients with Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy in China.
Clin Drug Investig. 2016 Jan;36(1):77-86. doi: 10.1007/s40261-015-0356-9.
5
Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment.
Cancer Manag Res. 2013 Jun 7;5:91-101. doi: 10.2147/CMAR.S32973. Print 2013.
6
Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer.
Cancer Manag Res. 2010 Jun 1;2:143-56. doi: 10.2147/cmar.s5398.
本文引用的文献
1
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19.
2
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
Lancet. 2009 May 2;373(9674):1525-31. doi: 10.1016/S0140-6736(09)60569-9.
3
Abandonment at the end of life from patient, caregiver, nurse, and physician perspectives: loss of continuity and lack of closure.
Arch Intern Med. 2009 Mar 9;169(5):474-9. doi: 10.1001/archinternmed.2008.583.
4
The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.
Oncologist. 2009 Mar;14(3):253-63. doi: 10.1634/theoncologist.2008-0232. Epub 2009 Feb 16.
5
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.
J Clin Oncol. 2009 Mar 10;27(8):1227-34. doi: 10.1200/JCO.2007.14.5466. Epub 2009 Feb 2.
6
Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer.
J Clin Oncol. 2009 Feb 1;27(4):591-8. doi: 10.1200/JCO.2008.17.1405. Epub 2008 Dec 15.
7
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
Lancet. 2008 Nov 22;372(9652):1809-18. doi: 10.1016/S0140-6736(08)61758-4.
8
Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer.
Clin Cancer Res. 2008 Oct 1;14(19):6317-23. doi: 10.1158/1078-0432.CCR-08-0539.
9
Missed opportunities for interval empathy in lung cancer communication.
Arch Intern Med. 2008 Sep 22;168(17):1853-8. doi: 10.1001/archinte.168.17.1853.
10
Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials.
J Clin Oncol. 2008 Oct 1;26(28):4617-25. doi: 10.1200/JCO.2008.17.7162. Epub 2008 Aug 4.
Zotero 插件